Combination therapy • IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • HOXA9 (Homeobox A9) • SYK (Spleen tyrosine kinase) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • MEIS1 (Meis Homeobox 1)
|
FLT3 mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement
|
Venclexta (venetoclax) • Xospata (gilteritinib) • entospletinib (GS-9973) • revumenib (SNDX-5613) • lanraplenib (GS-9876)